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Mathematical Analysis of Glioma 
Growth in a Murine Model
Erica M. Rutter1,2, Tracy L. Stepien  1,3, Barrett J. Anderies1,4, Jonathan D. Plasencia4, Eric 
C. Woolf5,6, Adrienne C. Scheck5,6,7, Gregory H. Turner8, Qingwei Liu8, David Frakes4, Vikram 
Kodibagkar4, Yang Kuang1, Mark C. Preul7 & Eric J. Kostelich1
Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice were injected with GL261-luc2 
cells, a cell line sharing characteristics of human glioblastoma multiforme (GBM). The mice were imaged 
using magnetic resonance (MR) at five separate time points to characterize growth and development 
of the tumor. After 25 days, the final tumor volumes of the mice varied from 12 mm3 to 62 mm3, even 
though mice were inoculated from the same tumor cell line under carefully controlled conditions. We 
generated hypotheses to explore large variances in final tumor size and tested them with our simple 
reaction-diffusion model in both a 3-dimensional (3D) finite difference method and a 2-dimensional 
(2D) level set method. The parameters obtained from a best-fit procedure, designed to yield simulated 
tumors as close as possible to the observed ones, vary by an order of magnitude between the three 
mice analyzed in detail. These differences may reflect morphological and biological variability in tumor 
growth, as well as errors in the mathematical model, perhaps from an oversimplification of the tumor 
dynamics or nonidentifiability of parameters. Our results generate parameters that match other 
experimental in vitro and in vivo measurements. Additionally, we calculate wave speed, which matches 
with other rat and human measurements.
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with mean survival time following diagno-
sis ranging from about 4 months with supportive care only1 to 15 months with standard treatment2, 3. GBM cells 
have both proliferative and migratory characteristics. Although surgical resection may remove the bulk of the 
original tumor, it has long been recognized that GBM cells migrate away from the main mass and penetrate the 
brain parenchyma4, forming recurrent tumors adjacent to and/or extending from the previous surgical resection 
bed.
GBM has been the subject of many previous mathematical modeling attempts. Work by Frieboes, Lowengrub, 
and their collaborators5–7 captures the angiogenic and invasive behavior of growing gliomas at the microscale. At 
the macroscale, human GBM is characterized by a diffusive as well as invasive growth pattern, for which partial 
differential equation (PDE) models are used. One early effort used a reaction-diffusion model to capture the gross 
behavior of GBM tumors as well as the effects of treatment8. Alvord9 was able to estimate the recurrence of GBM 
after resection using similar models.
One popular reaction-diffusion model is
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where u expresses a normalized tumor cell density (0 ≤ u(t, x) ≤ 1) at a particular time t and brain location x. 
The parameter D governs the rate of diffusion, and ρ, the growth rate of the tumor cell population. Swanson and 
her collaborators have explored the potential utility of equation (1) as a “patient specific” mathematical model to 
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estimate patient survival10 and to optimize treatment strategies11. They have attempted to estimate the parameter 
ρ and the ratio ρ/D from successive magnetic resonance (MR) images of individual patients: small values of the 
latter ratio appear to correspond to especially “diffuse” growth patterns, and larger values to more “nodular” 
tumors11. Such characterizations may predict which patients are likely to derive the greatest benefit from surgical 
resection12.
The mathematical modeling of human GBM is an inherently challenging enterprise. GBM may arise de novo 
or as a malignant progression from a preexisting lower-grade lesion13, and the extent of GBM invasion away from 
the main mass is difficult to ascertain from MR images14. Thus, the initial conditions in an individual patient case 
are uncertain. In addition, multiple genetic pathways are involved in the development and progression of GBM13. 
The expression of specific genes and gene pathways affect the rate at which GBM tumors proliferate and spread11. 
GBM invasion may also be facilitated by other cell types, including macrophages and microglia15. Thus, the ability 
to estimate growth and diffusion constants in any mathematical model of an individual tumor is limited. Finally, 
models like equation (1) do not explicitly account for immune response, genetic drift in the tumor, or the effects 
of treatment. Despite these shortcomings, equation (1) has the virtue of simplicity, particularly given the limited 
frequency of clinical imaging data and the uncertainties surrounding many of the biological details of GBM 
growth, progression, and treatment.
These considerations motivate the following controlled laboratory experiment. Using a well characterized 
murine glioma cell line (the details of which are provided in the methods section), we injected five mice intracra-
nially to provide tumor initial conditions that were as similar as possible. The growth of each tumor was followed 
in five successive MR imaging sessions designed to yield high-resolution images. Our objective is to determine 
how well simple models like equation (1) can predict the future growth of each mouse’s tumor using high-quality 
MR imaging alone, based on various assumptions of the initial conditions, tumor cell densities, and model 
parameters, as estimated from the images. Our simulations are performed in two and in three dimensions. We 
also characterize the uncertainties inherent in the predictions and in estimates of the model parameters using our 
methodology.
The GL261 cell line has been chosen because its diffusive and invasive growth characteristics in immunocom-
petent mice resemble those of human GBM16–18 and because it has been well studied (more details are given in 
the methods section). We report on our modeling results using data from three of the mice, due to difficulties in 
processing the images for the other two (see the methods section).
We begin by describing our mathematical models and the associated computational setup. This is followed 
by our description of the 3D finite difference model and results. Explanations of the 2D level set method and its 
results are described next. We then discuss the results and our future directions. At the end of the manuscript, we 
detail the methods and materials needed for generating the experimental data.
Mathematical Modeling
Overview of laboratory data and modeling frameworks. Figure 1 shows a representative T2-weighted 
MR image of each mouse at the last imaging session, 25 days after implantation. T2-weighted imaging produces 
image contrast where regions of increased water content in the tumor appear bright in the image. These bright 
regions indicate edematous brain tissue surrounding the tumor where the blood-brain barrier is disrupted, and 
in which there are spreading tumor cells. This method allows visualization and volume measurement with the 
use of contrast agents and is commonly used in clinical settings to evaluate the extent and mass effect of gliomas. 
Although each mouse was inoculated with approximately the same number of cells from the same culture, the 
visible volumes of the final tumors range from approximately 12 mm3 to 62 mm3, with considerable differences 
in mass effect. Table 1 shows estimated visible tumor volumes in T2-weighted images for each mouse at each 
of the five imaging time points. The sizes of the tumors diverge considerably during the last ten days of growth. 
Although our experimental sample is too small to provide meaningful statistics, our results suggest that there is 
significant variability in the in vivo progression of GL261 tumors from similar intracranial inoculations.
The discussion in this section compares the ability of two mathematical modeling frameworks to reproduce 
the experimentally observed growth and diffusion of the laboratory tumors using high-resolution, T2-weighted 
MR images. We compare a 3-dimensional (3D) finite difference method and a 2-dimensional (2D) level set 
method in terms of accuracy, as measured by the degree of overlap via the Jaccard distance (defined below) 
Figure 1. T2-weighted MR images taken 25 days after inoculation at the same location in the brain with respect 
to the initial needle track of the three mice used in this study. The left panel represents Mouse 1, the center, 
Mouse 2, and the right panel, Mouse 3. Despite inoculations with the same volume of tumor cells, the final 
tumors varied considerably in size.
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between the simulated and observed tumors in the appropriate computational domain. Our efforts may provide 
insight into nature of the model errors that may arise in the more complicated case of human GBM.
Early mathematical modeling of GBM growth and diffusion were based on reaction-diffusion equations. 
Tracqui et al.8 formulated the earliest reaction-diffusion model applied to GBM and simulated the effect of treat-
ment. Others expanded upon this basic model, incorporating a spatially-dependent diffusion coefficient that 
varied between gray and white matter tracts19, 20. These models are effective in determining the proliferating core 
of the tumor but are not as good at estimating the invasive front.
Later modeling efforts have incorporated a “go or grow” hypothesis, in which GBM tumor cell populations 
are assumed to consist of two phenotypes: a migratory subpopulation and a stationary, proliferative subpopu-
lation21, 22. In contrast, a recent paper23 shows that a model with a single tumor cell population, coupled with 
a density-dependent diffusion term, suffices to produce similar growth dynamics. The mathematical models 
described here incorporate only a single tumor cell phenotype, as our focus is on the predictive accuracy of equa-
tion (1), given its previous application to human GBM cases.
Recent in vivo modeling efforts have incorporated anisotropic diffusion and make use of diffusion-weighted 
imaging (DWI), which uses local diffusion of water molecules to generate image contrast. From the 6 (or more) 
diffusion images, a diffusion tensor can be created. This method, known as diffusion tensor imaging (DTI), ena-
bles the indirect measurement of local diffusion orientation and the degree of local diffusion anisotropy24. It 
is unclear how to relate water diffusion from DTI directly to tumor cell diffusion, though several groups have 
proposed various methods25–30. Other authors have considered a spatially dependent diffusion coefficient, with 
different values for regions of gray and white matter31. However, since mouse brains have a relatively uneven dis-
tribution of gray and white matter as compared to humans, we consider only a diffusion constant that is uniform 
in space. For a recent review on GBM modeling efforts, please see Martirosyan et al.32.
The simulations presented below are done in both 2D and 3D. The 3D simulations, presented first, represent 
our best efforts to capture the observed tumor volume of each mouse under three different hypotheses regard-
ing constant versus time-varying parameters. A limitation of the 3D approach is that we are unable to capture 
anisotropic effects of diffusion. We introduce a 2D model to examine how including anisotropic diffusion and 
time-dependent brain geometry alters our ability to reproduce the experimental data. Other researchers have had 
great success using 2D models33.
Computational Setup. Our 3D simulations use a finite-difference approach, in which the brain domain Ω 
consists of the imaged brain tissue with the ventricles segmented out. The notation x = (x, y, z) refers to the spatial 
location within Ω. For the 2D level set simulations, the domain is a plane as seen in one slice of an MR image, 
and x = (x, y). The boundary conditions in both cases are no-flux (the tumor does not penetrate the skull or the 
ventricles):
∂
∂
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Several considerations affect our choices of the initial conditions. Although we know how many cells were 
implanted intracranially, their initial distribution is difficult to ascertain, for two reasons. First, there may have 
been backsplash during the implantation process. The needle creates a divot into the brain through which tumor 
cells may flow back towards the surface of the brain. Second, although we know the cell concentration and per-
centage of viable cells in the initial inoculum, there may be differences from mouse to mouse in how many of 
those cells survived the implantation and began to grow. For this reason, the simulations described below are 
started from initial conditions based on the first imaging session of the tumor (day 11 after implantation).
The cell density within the enhancing regions corresponding to tumor is uncertain. We have assumed that 
u(t0, x) = 0.5, i.e., half the maximum density, within regions corresponding to visible tumor for each simulation 
interval starting at t0. Although this choice of initial density is arbitrary, the computational results are not espe-
cially sensitive to its value (more details are provided below).
Simulations are run from day 11 to day 25. Synthetic T2-weighted MR images are created by assuming that 
tumor cell densities greater than 0.16 (the carrying capacity is 1) correspond to “visible tumor” on the MR scan34. 
We compare the visible tumor volume on the synthetic MR images with that of the actual T2W MR images using 
an error function based on the Jaccard distance at each imaging time point. The Jaccard distance is a measure of 
the distance between two sets A and B at time t, given by
∩
∪
= − .d A B A B
A B
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J t,
Mouse
Day 11 volume 
(mm3)
Day 15 volume 
(mm3)
Day 18 volume 
(mm3)
Day 22 volume 
(mm3)
Day 25 volume 
(mm3)
1 0.715 1.155 4.980 15.570 25.460
2 0.595 3.025 4.320 8.095 12.340
3 0.970 3.855 16.485 30.675 61.490
Table 1. Volumes of visible tumor on MRI of each mouse at each time point.
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In this application, A is the set of voxels in the simulated MR image and B the set voxels corresponding to 
enhancing tumor. If A and B are disjoint, then dJ,t(A, B) = 1, and if A = B, then dJ, t(A, B) = 0.
Equation (1) contains two parameters: the proliferation rate ρ and the diffusion rate D. One natural question is 
whether, under suitable assumptions, these two parameters can be estimated from the MR data using the Jaccard 
distance as an error function. Furthermore, we want to quantify the uncertainties in the parameter estimates. The 
next section describes three different hypotheses regarding the time dependence of ρ and D and the results of a 
commonly used optimization algorithm to obtain a “best guess” of their values. One of our main results is that, 
although it is possible to find parameter values that provide a reasonably good fit to the observed MR images of 
each mouse, uncertainty quantification is problematic—and may have implications for clinical applications in 
human cases.
3D Finite Difference Model
As discussed in the methods section below, the computational domain Ω for each mouse is the linearly interpo-
lated uniform grid. The uniform grids of the brain and ventricles are imported into MATLAB. Then the ventricles 
are segmented out of the brain geometry to produce the computational domain. Since the ventricles have been 
segmented out, they are ignored in the discretization and no diffusion or growth occurs in the ventricular space, 
consistent with the boundary conditions. As the tumor grows, it begins to displace the surrounding brain tissue. 
At each scan session, the ventricles of each mouse brain have shifted slightly from the previous session due to 
mass effect. The gross anatomy of the brain has been registered; however, the internal structures, including the 
ventricles, shift due to mass effect of the growing tumor. We fix the locations of the ventricles to correspond to last 
MR scan in our computational geometry.
As mentioned above, we obtained usable time sequences of images for three mice, which we call Mouse 1, 2, 
and 3 in the results presented below. It is not possible to segment out the ventricles for the first two time points 
(days 11 and 15) for Mouse 3; simulation results for this mouse are carried out only for a truncated time period. 
(It is possible, however, to estimate the total visible tumor volume in all three mice at each time point, so Table 1 
gives a complete set of imaging volumes).
The model is discretized using centered finite differences in space. MATLAB’s ode45, a variable time-step, 
explicit Range-Kutta 4/5 solver, is a suitable integrator for this purpose. (Explicit schemes for finite difference 
methods are not always stable.) The space discretization is chosen to correspond to the pixel width in the post-
processed images. (The scans have a resolution of 0.1 mm × 0.1 mm × 0.5 mm). The full code is publicly available, 
as detailed at the end of the manuscript.
Simulation Hypotheses. We investigate the values of D and ρ necessary to approximate the observed 
experimental tumor volumes. From the segmented tumors in the MR images, we calculate the volume of the 
visible tumor in MIMICS based on the number of pixels that are segmented as tumor (Table 1). The final tumor 
sizes on day 25 vary from approximately 12 mm3 to 62 mm3, so we explore several hypotheses that may explain 
this observed range of values.
•	 Hypothesis 1: The natural variance in the growth rate ρ and diffusion rate D account for the large difference 
in final tumor size. In the first set of simulation results described below, we initialize the model based on the 
first MR imaging on day 11 following implantation. Our goal is to determine how well an optimized choice of 
constant (averaged) parameter values fits the observed images on day 25 and how well they agree with values 
estimated elsewhere in the literature.
•	 Hypothesis 2: The values of D and ρ are time dependent, corresponding to morphological changes during the 
growth of the tumors. A small tumor may be highly proliferative, but as the tumor grows and resources become 
scarce, the growth dynamics may be dominated by cell migration away from the main mass. In the second set 
of simulation results below, we attempt to optimize the values of D and ρ from time point to time point and 
see whether all of the mice display similar trends in the variation of these parameters.
•	 Hypothesis 3: In addition to the selection of optimized model parameters from one imaging time to the next, 
updates to the initial conditions at each imaging time point are made based on the visible tumor in each scan. 
This “predictor-corrector” approach is analogous to that used in operational weather forecasting, where the 
initial conditions of the weather model are updated periodically in view of incoming observations.
We optimize the vector of model parameters θ = (D, ρ) for each mouse individually using the fminsearch 
command in MATLAB under each of the three hypotheses. The optimization process seeks to minimize an error 
function based on the time average of the sum of the Jaccard distances, given by
∑ρ ρ=
=
E D
n
d A D t B t( , ) 1 ( ( , , ), ( ))
(4)k
n
J k k
1
where A(D, ρ, tk) corresponds to the enhancing voxels at time tk as predicted by model (1) for a given pair of 
parameters, and B(tk) corresponds to the voxels on the original MR image which are deemed to be enhancing at 
time tk. The summation is performed over all n time points for which imaging is available. For Mouse 1 and 2, 
there are n = 4 subsequent images at day 15, 18, 22, and 25 following implantation; for Mouse 3, there are n = 2 
subsequent images at days 22 and 25. As an example, Fig. 2 shows A in red and B in green for each hypothesis for 
each of the available MR image slices for Mouse 1 at time point 5, tk = 25 days after implantation.
Equation (4) measures only the extent of overlap of the enhancing region of the tumor. The actual tumor 
boundaries are larger, but the extent to which the glioma cells infiltrate the brain beyond the visible tumor mar-
gin in the T2-weighted images is unknown. Konukoglu et al.28 have suggested an estimation procedure based 
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on equation (1) to extrapolate the tumor cell density distribution beyond the visible margin in human GBM. 
Since we do not have histological data with which to compare, we measure only the enhancing volumes (“visible 
tumor”) for the murine gliomas. For the purposes of the simulations reported here, we assume that the detection 
threshold corresponds to u = 0.1634, but there is considerable uncertainty in this value. This question can be 
resolved only by correlating histology slides from the mouse brains with MR final images, a project that will be 
undertaken in future work.
Simulation Results. We present three sets of simulation results, each with a different hypothesis regarding 
the time evolution of the parameters D and ρ in model (1).
Hypothesis 1. Hypothesis 1 assumes that the tumor grows according to fixed values of the parameters D and ρ, 
but that these parameters may differ from mouse to mouse. We select initial conditions corresponding to the 
visible tumor at the first MR imaging session (day 11 following implantation). We use MATLAB’s fminsearch 
function to determine values of D and ρ that minimize the Jaccord distance error, equation (4), over the subse-
quent four imaging time points at days 15, 18, 22, and 25 following implantation. The resulting values, shown in 
Table  2,  range f rom ρ ρ= . = .− −0 0167 h to 0 0188h1 1 and from µ= .D 319 22 m /h2  (Mouse 2)  to 
µ= .D 651 17 m /h2  (Mouse 3).
Figure 2 part (a) superimposes the simulated tumor in red, and the experimentally segmented tumor in green, 
over representative MR images at the last imaging time point for Mouse 1. The Jaccard distance error is 
ρ = .E D( , ) 0 4524. The full time point fits for Mouse 1 (Supplementary Fig. S1), Mouse 2 (Supplementary Fig. S4) 
and Mouse 3 (Supplemenary Fig. S7), are shown in the Supplementary Figures.
Hypothesis 2. Hypothesis 2 asserts that there may be a morphological change that occurs sometime within the 
tumor growth process that changes the values of D and ρ. The tumor grows more quickly when it is small, but as 
time proceeds and resources become scarce, the growth rate may slow.
The parameter estimation procedure under this hypothesis proceeds in a similar way to that in Hypothesis 1, 
except that the parameter optimizations are done between successive imaging time points. That is, we take the 
same initial conditions on Day 11, then run fminsearch to minimize E(D, ρ) at day 15 only. Then, starting with the 
simulated tumor at day 15, we select parameter values to minimize E(D, ρ) at Day 18, and so on. Table 2 shows all 
the results,  which for Mouse 1 gives the est imates ρ = . . . . −0 0182, 0 0248, 0 0192, 0 0082 h 1,  and 
µ= . . . .D 139 24, 839 93, 1047 6, 968 75 m /h2  for the Day 11–15, 15–18, 18–21, and 21–25 time intervals, respec-
tively. The sum of the individual Jaccard error measures, equation (4), is 0.4365, representing a 3.5% decrease in 
Jaccard distance from Hypothesis 1. Figure 2 part (b) shows the results for Mouse 1 for day 25, the last time point. 
The results suggest that there is a significant temporal variation in the model parameters as the tumor evolves. 
However, the model’s ability to track the visible tumor is only slightly improved compared to Hypothesis 1. The fit 
Figure 2. Representative simulation results for Mouse 1 at day 25 following implantation under (a) Hypothesis 
1, (b) Hypothesis 2, and (c) Hypothesis 3. The simulated enhancing tumor volume is shown in red, and the 
segmented regions of enhancement in the laboratory tumor in green for eight different slices of the MR images.
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for all time points for Hypothesis 2 for Mouse 1 (Supplementary Fig. S2), Mouse 2 (Supplementary Fig. S5) and 
Mouse 3 (Supplementary Fig. S8) are available in the Supplementary Figures.
Hypothesis 3. Hypothesis 3 also asserts that D and ρ to vary with time, but the model is restarted from new initial 
conditions each time. That is, we optimize the parameters from time point to time point as in Hypothesis 2, but in 
addition, we reset the initial conditions at each imaging time point, under the assumption that tumor cell densities 
at and above 0.16 correspond to visible tumor on T2-weighted images. The optimized estimates for Mouse 1 for the 
growth rate are ρ = . . . . −0 0182, 0 0499, 0 0178, 0 0105 h 1 and µ= . . . .D 139 24,233 97,1156 2,1305 6 m /h2  for the Day 
11–15, 15–18, 18–21, and 21–25 time intervals, respectively. The sum of the individual Jaccard error measures (4), 
based on the predicted images prior to the initial condition updates, is 0.3663, representing a decrease of 18.8% from 
Hypothesis 1. Figure 2 part (c) shows the results for Mouse 1 at the last time point, day 25. For full results of 
Hypothesis 3, see the supplementary figures for Mouse 1 (Supplementary Fig. S3), Mouse 2 (Supplementary Fig. S6), 
and Mouse 3 (Supplementary Fig. S9).
For two of the three mice, the diffusion coefficient appears to increase over time. However, for Mouse 2, the 
optimized values for D decrease significantly over the last two time points, but the growth parameter ρ increases 
sharply. This result may reflect a biological difference in the growth dynamics of Mouse 2’s tumor compared to 
the others.
Velocity of Tumor Boundary. Since our analysis of Hypotheses 1–3 in the previous sections indicates that assum-
ing constant D and ρ is inadequate to accurately model tumor growth and diffusion, we examine the dependence 
of the velocity of the visible tumor boundary on the volume to determine if the estimated parameters correlate 
with the volume of the tumor.
Model (1) implies that the tumor boundary moves as a traveling wave whose wave speed (velocity) is ρD2 . 
Figure 3 shows a plot of the predicted wave speed versus the visible tumor boundaries under each set of modeling 
hypotheses. The data points are separated by shape and color: blue markers correspond to the wave speeds calcu-
lated for Hypothesis 2 and red markers correspond to the wave speeds generated from Hypothesis 3. Within these 
colors, the markers signify the separate mice: Mouse 1 is represented by triangles, Mouse 2 with plusses, and 
Mouse 3 with circles. At first glance, it may appear that there is little correlation between the two variables. 
However, if we examine the Hypothesis-3 data (red markers), we can see there does appear to be some relation-
ship between wave speed and visible tumor size. More data are necessary to quantify the relationship, however.
Identifiability of Parameters. The minimization procedure described above yields estimates of the param-
eters D and ρ for equation (1) that are reasonably consistent with the experimental data. However, the procedure 
does not provide confidence intervals for the parameters. We turn to this question now.
Mouse Hypothesis
Time 
Point D (μm2/h) ρ (h−1)
velocity ρD2
(μm/h) Error
1
1 — 413.77 0.0188 5.5781 0.4524
2
2 139.24 0.0182 3.1838 0.1196
3 839.93 0.0248 9.1280 0.1191
4 1047.6 0.0192 8.9697 0.1029
5 968.75 0.0082 5.6369 0.0949
3
2 139.24 0.0182 3.1838 0.1196
3 233.97 0.0499 6.8338 0.1145
4 1156.2 0.0178 9.0731 0.0688
5 1305.6 0.0105 7.4051 0.0644
2
1 — 319.22 0.0167 4.6178 0.4528
2
2 558.74 0.0235 7.2472 0.1151
3 206.21 0.0100 2.8720 0.1067
4 346.35 0.0055 2.7604 0.1042
5 886.07 0.0104 6.0713 0.0979
3
2 558.74 0.0235 7.2472 0.1151
3 950.79 0.0051 4.4041 0.0846
4 77.734 0.0369 3.3873 0.0621
5 94.161 0.0520 4.4255 0.0643
3
1 — 651.17 0.0177 6.7899 0.2833
2
4 859.70 0.0127 6.6085 0.1408
5 454.29 0.0236 6.5487 0.1364
3
4 859.704 0.0127 6.6085 0.1408
5 1552.1 0.0200 11.1431 0.1027
Table 2. Values of estimated parameters for Mouse 1, 2, and 3 and each hypothesis at each time point using the 
3D finite difference method. Minimization is performed with respect to equation (4).
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Let u(t, θ) denote the output of a mathematical model at time t given a vector of parameters θ, whose compo-
nents may include initial conditions, rate coefficients, and other model-related constants. Following Raue et al.35, 
one common approach to measuring the goodness of fit is to define a residual function of the form
∑ ∑χ θ
θ
σ
=



− 

= =
y t u t
( )
( ) ( , )
,
(5)i
n
k
p
k i k i
ki
2
1 1
2
where θu t( , )k i  is the model prediction of the k th observable at time ti, yk(ti) is the corresponding measurement, 
and σki is the standard error in yk(ti). The parameter estimate is θ = argminχ2(θ), which may be regarded as the 
minimizer of a likelihood function when the measurement noise is unbiased and gaussian.
The parameter vector θ is identifiable if θˆ  is unique for a given set of measurements and associated uncertain-
ties. The components of θ may be nonidentifiable if one or more of them is an implicit function of the others, or if 
the set of observables is insufficient to find a unique minimizer of equation (5). In addition, θ may be practically 
nonidentifiable35 if the uncertainties σki are large enough to make it difficult to distinguish between possible min-
imizers, i.e., the value of χ2(θ) changes little for a large range of θ.
In our case, it is difficult to define a sum of squares like equation (5), because we do not know the correlation 
between the tumor cell density and the degree of MR enhancement within each voxel, and so we cannot define an 
associated standard error. Instead, our simulation and measurement thresholds are binary: a given grid point in 
the computational domain contains tumor cells above a detectable threshold or it does not, and each pixel of the 
corresponding MR image either shows enhancement or it does not.
Figure 4 shows a plot, for each of the three mice, of E(D, ρ) (equation (4)) for D and ρ in the indicated inter-
vals. The values of E(D, ρ) are color-coded from deep blue (smaller values, corresponding to smaller Jaccard 
distances between predicted and observed regions of visible tumor) to deep red (larger values, corresponding to 
larger Jaccard distances). In each case, there is a deep blue “valley” of minimal values of E(D, ρ), which suggests 
that the parameters ρ and D in equation (1) are nonidentifiable: many choices of the parameters are consistent 
with the available data. Consequently, it is not possible to formulate confidence intervals around the values of D 
and ρ obtained from the error minimization procedure described above.
Model (1) implies that the tumor front expands like a traveling wave with wave speed ρ=c D2 . The “opti-
mal” value of c for each mouse is derived from the minimization procedure in the previous section and appears in 
Figure 3. Dependence of wave speed of tumor on tumor size. The wave speed (velocity) of the tumor is 
calculated by ρD2 . Blue markers show results from parameters optimized under Hypothesis 2; red markers, 
Hypothesis 3. Triangles: Mouse 1; pluses: Mouse 2; circles: Mouse 3.
Figure 4. Plots of E(D, ρ) (equation (4)) for Hypothesis 1 for Mouse 1 (left), Mouse 2 (center), and Mouse 3 
(right) for selected intervals of the model parameters D and ρ. The red line represents the wave speed, ρD2 , for 
the “optimized” values of D and ρ.
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the sixth column of Table 2. Under Hypothesis 1, c is constant throughout the simulation. Superimposed on each 
plot in Fig. 4 is a red arc showing the values of D and ρ corresponding to the wave speed c obtained from the cor-
responding mouse (i.e., ρ =D c D( ) /42 ) for a selected interval of D. The results for Mouse 3 suggest that c may be 
identifiable in some cases, as the arc corresponds approximately to the smallest values of E(D, ρ) in the indicated 
range.
Although the parameters ρ and D for our tumor growth model cannot be estimated uniquely using the avail-
able imaging data, they may be possible to estimate from additional types of measurements, such as tumor cell 
counts from cell histology. Such measurements may define a quantitative relationship between the degree of 
image enhancement and tumor cell density. Such efforts will be the subject of future research.
Initial Condition Sensitivity Analysis. We have performed additional analyses to determine the sensitiv-
ity of the parameter estimation procedure to the choice of initial condition. Using Mouse 1, we have repeated the 
parameter estimation procedure assuming that the voxels corresponding to visible tumor are at 0.3 and 0.7 of the 
carrying capacity. The results, shown in Table 3, are rather insensitive to the initial starting densities. Although the 
estimated values of D increase with the initial cell density, the values of ρ decrease: a high initial density of cells 
supports more diffusion and less growth. Nevertheless, the predicted wave speeds given by ρD2 , are all approx-
imately the same.
2D Level Set Method Model
Modifications to Model Equations. This section describes a reformulation of the model (1) as a two-di-
mensional free boundary problem, also known as a Stefan problem. Although our data are three dimensional, 
we examine two-dimensional coronal, sagittal, and transverse (horizontal) sections to explore the effects of ani-
sotropy and time-dependent brain geometry on the growth of the simulated tumor and to determine whether 
a two-dimensional model can capture projections of the three-dimensional movement. The Stefan problem was 
first derived for the transfer of heat during solidification or melting processes where the boundary is the phase 
boundary separating regions of different temperatures. More recently, free boundary problems have been studied 
in the context of wound healing and tumor growth33, 36–40.
We assume the governing equation for brain tumor growth is equation (1), where the tumor domain, denoted 
Ωt1, is time dependent; Ω1
0 consists of those locations where tumor is visible on the initial scan at day 11. The 
remainder of the brain is denoted Ωt2; see Fig. 5.
Similar to the three-dimensional simulations discussed previously, the initial condition is
= . ∈ Ωu x x(0, ) 0 5, ,1
0
in interior regions of the enhancing tumor, and
= . ∈ ∂Ωu x x(0, ) 0 16, ,1
0
Initial Condition 
Cell Density (%) D (μm2/h) ρ (h−1)
velocity ρD2  
(μm/h) Error
30 316.43 0.0226 5.3484 0.4510
50 413.77 0.0188 5.5781 0.4524
70 441.52 0.0168 5.4476 0.4592
Table 3. Values of estimated parameters for Mouse 1 using initial condition cell densities for Hypothesis 1. 
Minimization is performed with respect to equation (4).
Figure 5. Schematic illustration of the computational domain of the moving boundary initial value problem for 
tumor growth. The blue area (Ωt1) represents the tumor cells, the light gray area represents the ventricles, the red 
area (Ωt2) represents the remainder of the brain, and the dark gray represents the area outside of the brain.
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on the boundary, corresponding to the hypothesized detection threshold u = 0.1634 from T2-weighted images. 
The no-flux boundary condition is
∇ ⋅ = ∂Ωu n 0, on , (6)t2 2
where n2 is the unit normal to the boundary Ωt2.
We assume that the velocity of the tumor boundary v(t, x) is governed by Darcy’s law, µ= − ∇pv , where μ 
may be interpreted as the cellular mobility, assumed equal to D to avoid an extra model parameter. The 
tumor-generated pressure ρ is modeled by ρ ρ=p( ) ln( ). This choice of pressure allows for an arbitrarily large 
stress to stretch and compress of the tumor tissue. These assumptions lead to the Stefan condition
⋅ = −





∇ ⋅ ∂Ω¯
D
u
uv n n , on ,
(7)
t
1 1 1
where = .u 0 16 and n1 is the unit normal to the boundary Ωt1. The calculation of the velocity of the boundary of 
the visible tumor here depends on equation (7), not on the value ρD2  as in the case of the 3D finite difference 
model. Because the ventricles are displaced while the tumor moves, the geometry of Ωt2 is updated in time on days 
15, 18, 22, and 25 directly from the corresponding MR scans.
A numerical solution of the Stefan problem for a given tumor and parameters D and ρ is computed using a 
level set method introduced by Osher and Sethian41 and applied to Stefan problems by Chen et al.42, Javierre et 
al.43, and Arciero et al.44, among others. Supplementary Methods S3 contains full details of the solution method.
Results
To fit the mathematical model in the previous section to experimental data of tumor growth in 2D sections of 
mice brains, we estimate the model parameters D and ρ by minimizing the Jaccard distance error, equation (3), 
and the mean-squared difference between the boundary points of the numerical simulation and the experimental 
data,
∑ ∑=





= =
z
d
Ld t h
L
h t
2
5
1
min, ,
2 1/2
where the minimum distance dmin, h, t is calculated by minimizing the distance between every point h on the 
numerical boundary to every line segment along the data boundary at each imaging time point t (days 15, 18, 
22, and 25). The boundary of the simulated tumor is easier to define than in the three-dimensional simulations, 
but the extent to which tumor cells have diffused beyond the visible edge is unknown. The weighted total error 
is given by
∑ρ = +
=
E D z d A B( , ) 10 ( , ),
(8)d t
J t2
2
5
,
which is minimized as a function of the model parameters D and ρ using the MATLAB command fminsearch. 
The factor of 10 is included so that the error term from the boundary positions is of the same order as the Jaccard 
distance.
We have fitted the experimental and numerical tumor edge positions by choosing D and ρ to minimize E2 for 
Mouse 1 using 4 transverse, 2 sagittal, and 2 coronal sections and for Mouse 2 using 8 transverse, 7 sagittal, and 3 
coronal sections. These are all the sections that contain contrast-enhancing tumor over all time points. This anal-
ysis corresponds to Hypothesis 1 from the 3D finite difference simulations. Furthermore, the slices for which we 
can estimate parameters using the 2D level set method depend on whether the tumor has spread predominately 
radially in that section. Due to the software difficulties in obtaining ventricle data as previously described, we did 
not perform this analysis on Mouse 3. The estimated parameters are plotted in Fig. 6(a,c). The velocity of the 
tumor front as a function of the relative invasiveness, defined as ρDlog ( / )10
12, is plotted in Fig. 6(b,d). Table 4 
displays all the computed values for D, ρ, and tumor velocity. The values of D and ρ appear to be independent of 
the choice of coronal, axial, or sagittal section, which suggests that there is no preferential direction for tumor 
growth. However, because the estimated parameter values vary throughout the brain, the results also imply that 
the tumor growth patterns are heterogeneous and cannot be well-modeled using constant values for the parame-
ters D and ρ.
The intrinsic heterogeneity of the tumor growth pattern becomes apparent in the numerical simulations given 
in Fig. 7. Under the assumption of isotropic media, as described in the previous section, the level set method pro-
duces simulated movement that is symmetric and, in general, has a limiting elliptical shape, as shown by the solid 
blue curves in Fig. 7. The numerical simulations match the experimental tumors, shown by the dotted red curves, 
only if the observed tumor does not show a preferential direction for growth.
A contrasting simulation, in which the diffusion constant D varies spatially, is shown in Fig. 8. At each voxel, 
D is chosen randomly from a uniform distribution. In the horizontal direction on the left half of the computa-
tional domain for the brain section (as in Fig. 8), D is in the interval [0,0.2η], where η µ= 11120 m /h2 , the same 
value of D given in Table 4 for Mouse 2, coronal slice 2. In the horizontal direction on the right half of the brain 
section, D is in [0,0.05η]. In the vertical direction, on the top half D is in [0.1η, 0.4η], and on the bottom half D is 
in [0.3η, 0.5η]. The average error E2 from equation (8) for 15 simulations is 70.66, which is smaller for this aniso-
tropic case compared to the isotropic case given in Fig. 7(c). Although the error contribution from the Jaccard 
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distance is not much different, the error contribution from the difference in boundary positions is smaller in the 
anisotropic case. The shapes of the tumor boundaries arising from the anisotropic assumption are a better match 
to the experimental data than the 3D simulations.
As with the 3D finite-difference method, we would like to determine whether the parameters are identifi-
able using our error function given by equation (8). Following the methods outlined in the previous section, 
Identifiability of Parameters, we created surface likelihoods for a subset of the 2D slices and parameter values. It 
appears that D and ρ remain non-identifiable for certain intervals of parameters.
Figure 6. Parameter values for Mouse 1 and 2 from the 2D level set method. Estimated parameter values for 
various 2D slices as reported in Table 4: (a) Mouse 1 and (c) Mouse 2. The parameter estimation routine was run 
for various initial parameter value guesses, and the size of the data points corresponds to the magnitude of the 
error in equation (8). Radial velocity of the tumor taken from the last simulated day of movement versus relative 
invasiveness: (b) Mouse 1 and (d) Mouse 2.
Mouse Section Slice D (μm2/h) ρ (h−1) velocity (μm/h) Error
1
Transverse
1 463.09 0.027164 3.6967 103.23
2 554.98 0.02052 3.425 99.92
3 3074.8 0.015377 5.4098 80.24
4 2923.1 0.010395 3.8589 82.02
Sagittal
1 305.51 0.0063098 1.2091 127.85
2 626.77 0.0011284 0.3342 119.51
Coronal
1 91.762 0.10424 2.8026 94.81
2 336.48 0.034115 2.7293 91.14
2
Transverse
1 534.97 0.017231 3.0134 75.99
2 2955.1 0.011975 4.0672 71.22
3 3171.1 0.01068 3.7663 74.35
4 3261.4 0.0074994 2.8306 73.75
5 598.27 0.0084187 1.4412 67.44
6 558.54 0.009343 1.3758 64.72
7 1284.4 0.000037942 2.2519 71.19
8 530.47 0.013664 2.21 68.79
Sagittal
1 10984 0.0080234 4.2752 91.78
2 1656.4 0.0037629 1.6703 87.20
3 837.34 0.0070626 1.9906 73.21
4 3098.5 0.0050553 2.2666 78.46
5 83.08 0.070895 2.5196 107.28
6 525 0.015 2.7293 115.82
7 111.77 0.11002 3.7248 105.85
Coronal
1 8317.9 0.004686 1.9781 84.79
2 11120 0.007827 4.0281 79.72
3 370.53 0.031518 3.6641 97.47
Table 4. Values of estimated parameters for Mouse 1 and 2 and Hypothesis 1 using the 2D level set method. 
Minimization is performed with respect to equation (8).
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Discussion and Conclusions
In this study, we examine a laboratory murine model of GBM tumor growth, in which genetically similar, immu-
nocompetent mice received identical intracranial injections from the same culture of a GL261-luc2 tumor line. 
The growth patterns of the resulting tumors vary considerably. From experimental MR images, we investigate two 
mathematical models and examine their ability to simulate the laboratory results under various choices of model 
parameters. The reaction-diffusion model, equation (1), is numerically integrated using a finite difference method 
in three dimensions. In two dimensions, an extension of equation (1) that incorporates a free boundary and an 
anisotropic domain is numerically integrated using a level set method.
Previous estimates of the growth parameter ρ is approximately in the range 0.014–0.018 h−1 for in vitro 
GL261-luc2 cells45 and 0.0096–0.011 h−1 for in vivo GL261-luc2 cells46. The estimated values for ρ in both sets of 
our simulations, presented in Tables 2 and 4, is comparable to these values.
Measurements of the apparent diffusion constant (ADC) for in vivo GL261-luc2 cells, which is calculated from 
diffusion weighted imaging that maps the diffusion of water molecules, range from 2.2–3.3 mm2/h47, 48. These 
values are orders of magnitude larger than the diffusion constant D estimated from our simulations in Tables 2 
and 4. A more meaningful comparison between the two types of measurements requires a quantitative correlation 
Figure 7. Simulation of 2D level set method for Mouse 2 with isotropic diffusion. Tumor boundary movement 
in Mouse 2 in select slices with estimated parameters from Table 4. The red dotted curve represents the tumor 
boundary from the laboratory imaging and the solid blue curve, the boundary from the 2D mathematical 
model. The light gray regions are ventricles and the dark gray regions are outside of the brain. (a) Transverse 
section; (b) sagittal section; (c) coronal section.
Figure 8. Simulation of 2D level set method for Mouse 2 with anisotropic diffusion. Tumor boundary 
movement in Mouse 2 in the same slice as Fig. 7(c) but with a spatially dependent value of the diffusion 
parameter D. Solid blue curve: numerical simulation; dotted red curve: actual tumor boundary. The light gray 
regions are ventricles and the dark gray regions are outside of the brain.
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between the diffusion of water in DWI images and the growth of the tumor over time, which likely will require cell 
density measurements from histology. Our largest value of D is still considerably less than previously published 
values, which suggests that errors in the initial conditions and in the assumptions on the correspondence between 
tumor cell densities and enhancing regions on MR images are contributing factors. Our assumption regarding the 
minimum cell density that is visible on MR may need to be revised significantly. The result of nonidentifiability 
of parameter estimations supports that more work must be done to quantify this relationship. Additionally, since 
parameter identifiability may depend on the initial condition of the system, revising our estimations of initial 
tumor cell density on enhancing regions of MR images on day 11 may alter the parameter identifiability results.
The 3D finite difference method applied to equation (1) implies that the velocity of the visible tumor boundary 
is ρD2 , while the tumor boundary in a 2D level set method is estimated from the Stefan condition, equation (7). 
Converting to units of centimeters per year from Table 2, the 3D finite difference method yields velocity estimates 
from 2.789–7.996 cm/yr for Mouse 1, 2.516–6.348 cm/yr for Mouse 2, and 5.737–9.761 cm/yr for Mouse 3. In 
contrast, the 2D level set method produces the velocity estimates from 0.213–3.441 cm/yr for Mouse 1 and 0.875–
2.719 cm/yr for Mouse 2 (see Table 4). The latter estimates are closer to those obtained from tumors in rat brains 
with implanted human glioblastoma cells49 and are on the low end of the human velocity range50, 51.
Within the 3D finite difference method, we formulated three hypotheses as to what contributed to the 
growth of the glioma in the murine brain. We noticed improvements, as measured by the Jaccard distance, from 
Hypothesis 2 (time-varying parameters) over Hypothesis 1 (constant parameters) of, on average, 4% (range 2.15– 
6.38%). Similarly, we noticed improvements from Hypothesis 3 (short-term simulations) over Hypothesis 1 of, 
on average, 20.3% (range 14.05–27.98%).
From the preceding work, we draw the following conclusions.
•	 T2-weighted imaging alone is insufficient to uniquely estimate the model parameters in equation (1). Addi-
tional types of measurements are necessary to formulate confidence intervals on model parameters and asso-
ciated predictions.
•	 Cancer cell densities derived from histology (stained microscope slices of the mouse brains), correlated with 
the MR imaging, may provide much more precise information about tumor cell distributions with which to 
evaluate the accuracy of associated mathematical models. These correlational data may permit a statistical 
characterization between tumor cell density and MR intensity enhancement that can make MR imaging data 
more useful for estimating initial conditions and identifying the model parameters. Finally, histological data 
may permit the formulation of more biologically realistic models.
•	 By performing simulations in two and three dimensions, we find comparable estimates of the model param-
eters D and ρ from the experimental data. This result suggests that the details of the time-varying geometry 
and mass effect omitted from our 3D simulations do not significantly affect the estimates of the model param-
eters. (A future laboratory effort involving more mice, as well as a 3D model incorporating mass effect, are 
needed to confirm this assertion).
•	 As a model for glioma growth, model (1) requires diffusion and proliferation parameters that vary with time. 
At the least, simulations with piecewise constant parameters maximize the overlap, measured by Jaccard 
distance, between the predicted and observed tumors. In particular, the simulation results under Hypothesis 
3 suggest that incorporating periodic updates of initial conditions from MR imaging eventually may be a 
feasible way to make useful short-term predictions of the evolution of individual tumors. Accurate long-term 
predictions of tumor growth do not appear to be possible using our methodology.
•	 Model (1) is the simplest PDE to describe the dynamics of a diffusive, logistic growth process. Our results sug-
gest that a somewhat more sophisticated model should include anisotropic diffusion. A density-dependent 
diffusion term may also be appropriate23.
If, after a careful histological examination of tumors from a future experimental effort involving more mice, it 
proves possible to determine a statistical correspondence between the local tumor cell density and MR imaging, 
then more sophisticated data assimilation methods can be applied to provide short-term forecasts of the evolution 
of the tumor, including predictions of the distribution of tumor cells in regions beyond the visible tumor bound-
ary52. Finally, future research that elucidates additional details of glioma biology can inform potential improve-
ments to model (1) to account for interactions with the immune system, genetic drift within the tumor cells, and 
other factors.
Methods
Animals and Care. The study follows the guidelines and regulations set by the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals53 and approved by the Institutional Animal Care and Use 
Committee at the Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center. All aspects of 
the experiments including animal housing, surgeries, imaging, and euthanasia were carried out at the Barrow 
Neurological Institute at St. Joseph’s Hospital and Medical Center. The animals had continuous free access to food 
and water.
GL261-Luc2 Tumor Cell Line. The GL261-luc2/C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) tumor model 
has been chosen because it is an established glioma model that is recommended for preclinical GBM therapy 
studies54. GL261-luc2 is a syngeneic tumor cell line originally developed within the immunocompetent C57BL/6J 
mouse strain16, 54–57. Seligman and Shear originally promoted the GL261 tumor cell line in the C57BL/6J mouse 
by implanting 3-methylcholanthrene pellets into the brains of mice in the 1930’s16, 54, 55. The GL261 cell line within 
the immunocompetent C57BL/6J mouse strain thus produces a more typical immune response to the glioma and 
is thought to involve a pathological progression of malignant glioma akin to that in humans. The GL261 cell line 
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is an aggressive tumor that shares many characteristics similar to the human GBM: tumor necrosis, hemorrhages, 
angiogenesis, cellular proliferation, invasion, and inflammation16–18. Although GL261 has a tumoral cell rim, it 
is not the typical pseudopalisading architecture seen in human GBM17. However, gross cellular proliferation and 
invasion are the most important biological characteristics for this study in the context of modeling cellular growth 
and migration.
GL261 cells were obtained from the DCTD Tumor Repository (NCI, Frederick, MD) and grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) at 37 °C with 5% CO2. To facil-
itate a quantitative measurement of tumor growth rate, GL261 cells were stably transfected with the gene encod-
ing Luc2 using the pGL4.51[luc2/CMV/Neo] vector (Promega Corp, Madison, WI) and FuGENE® 6 Transfection 
Reagent (Roche Applied Science, Indianapolis, IN) following conditions specified by the manufacturer. Stable 
transfectants were selected and maintained in DMEM containing 10% FCS and 100 μg/ml Geneticin® (G418, 
Invitrogen Corp, Carlsbad, CA). These cells were designated GL261-Luc2; their growth rate is equivalent to the 
parental GL261 cell line16, 58.
Implantation. GL261-Luc2 cells were harvested by trypsinization, washed and resuspended at a con-
centration of 1–2 × 107 cells/ml in DMEM without FCS and implanted into ten-week-old immunocompetent 
C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice (The Jackson Laboratory, Bar Harbor, ME, USA) with an average 
weight of 20 g. Briefly, the animals were anesthetized by an intraperitoneal injection of ketamine (10 mg/kg) and 
xylazine (80 mg/kg), placed in a stereotactic apparatus, and an incision was made over the cranial midline. A bur-
rhole was made 0.1 mm posterior to the bregma and 2.3 mm to the right of the midline. A needle was inserted to a 
depth of 3 mm and withdrawn 0.4 mm to a depth of 2.6 mm. Two μl of GL261-Luc2 cells (1–2 × 104 cells/μl) were 
infused over the course of 3 minutes. The burrhole was closed with bonewax and the incision was sutured. The 
mice were housed in groups of five in the animal care facility at St. Joseph’s Hospital and Medical Center in rooms 
with controlled temperature and humidity under a 12-hour light-dark cycle according to the guidelines outlined 
in the NIH Guide for Care and Use of Laboratory Animals53. Complete methods describing the GL261-Luc2 
implantation into C57BL/6J mice have been previously published16.
MR Imaging. Tumor bioluminescence and MR imaging were performed under isoflurane anesthesia on 
days 11, 15, 18, 22, and 25 after the initial intracranial injection. These imaging intervals were chosen to obtain 
frequent snapshots of the growing tumor in a manner that, in the experimentalists’ judgment, would not be 
detrimental to the health of the mice. For each imaging session, anesthesia was induced and maintained under 
isoflurane (1–2%) in oxygen. Respiration was continually monitored with a pillow sensor position under the 
abdomen (SA Instruments, Stony Brook, NY), and normal body temperature was maintained with a circulating 
warm water blanket (Thermo Scientific, Rockford, IL). The animals were stabilized with ear and tooth bars to 
minimize any motion and to ensure accurate image-to-anatomy registration. We present full details of the labo-
ratory imaging here, although we have used only the T2-weighted images in this paper. Subsequent work will use 
this information to formulate more complex model frameworks.
Prior to MR imaging, bioluminescent tumor signal was measured. Animals received a subcutaneous injection 
of 150 μg luciferin/kg body weight 15 min prior to in vivo imaging using an IVIS® Spectrum in vivo imaging 
system (Perkin Elmer, Waltham, MA). Images were acquired and analyzed using the system’s Living Image® 4.0 
software.
MR images were acquired using a Bruker BioSpin 7T system in the following sequential order for each imaging 
session: high resolution T2-weighted (T2W), diffusion weighted (DW), T2W series, T1-weighted (T1W) series, 
dynamic contrast enhancement (DCE), and post contrast T1W. In the following discussion regarding imaging, 
we report the dimensions as axial × sagittal × coronal. High resolution T2W images (0.1 mm × 0.1 mm × 0.5 mm 
voxels) were acquired as a reference between time points. The DWI data series was acquired in 6 diffusion direc-
tions with a resolution of 0.2 mm × 0.2 mm × 1.0 mm. The T1W and T2W image series were acquired for T1 
and T2 mapping, respectively. The resolution for these images was 0.2 mm × 0.2 mm × 0.5 mm. The DCE was 
continuously acquired for approximately 21 min, with the scientist needing to enter the MR room at 1.5 min into 
the acquisition to deliver a subcutaneous injection of a 1 ml bolus of contrast agent (i.e., Gd-DPTA (0.04 mol/ml)) 
through a preset catheter in the neck. The first 1.5 min of the DCE scan series was used as a pre-contrast baseline. 
The injections were completed approximately 2 min into the DCE acquisition. The resolution for these images 
was 0.2 mm × 0.2 mm × 0.5 mm. The full set of MRI parameters is provided in detail in Supplementary Data S1. 
Representative examples of the MR images are displayed in Fig. 1.
Tissue Procurement and Histology. The mice were euthanized on day 26 using deep anesthesia with 
isoflurane followed by decapitation. The brains were carefully removed to minimize damage and were immedi-
ately placed in a 4% paraformaldehyde solution for 48 hours. The sample was then placed in a phosphate-buffered 
saline and submitted to St. Joseph’s Hospital and Medical Center’s histology lab for dehydration and paraffin 
embedding.
Image Preprocessing. The brain, ventricle, and tumor spaces were segmented from the high resolution 
T2W images using the medical image processing software MIMICS® (Materials Inc, Leuven, Belgium). The seg-
mented spaces were then exported as STL files, i.e., as surface meshes.
The brain surface meshes were used in two subsequent steps. First, the brain surface mesh from a given time 
point was imported back into MIMICS to identify and ultimately export point clouds of the intensity values 
included in all original images acquired during the same time point’s MR session. Second, brain meshes for a sin-
gle animal at different time points were co-registered using the best-fit function in Geomagic® Studio (Geomagic 
Inc, NC). Specifically, the brain volumes were registered to the mid-time point, day 18. For each time point and 
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for each mouse, Geomagic exported an affine matrix describing the necessary rotation, scaling, reflection, and 
shearing necessary to transform the surface of a given brain to the registered brain (which is the identity matrix 
for the third time point, day 18).
The exported affine matrices were then used to transform the corresponding resulting point clouds in 
MATLAB, so that the location of the brain for each mouse was constant. The transformed data points, con-
taining intensity values, were then linearly interpolated to a uniform grid. The spacing of the grid is 
0.1 mm × 0.1 mm × 0.5 mm to match the T2W image spacing, which allows for easy comparisons. This uniform 
grid is then used for the 3D finite difference and 2D level set methods described above.
Availability of Data. The full datasets used in this article are available in the Open Science Framework 
Repository, https://osf.io/r78e4/.
Availability of Computer Code. The 3D finite difference code used to generate the results for this arti-
cle is available in the murine-GL261-tumors repository located on github, https://github.com/banderie/
murine-GL261-tumors. The code is platform independent and written in MATLAB, which requires a license.
The 2D level set code used in this work may be made available by contacting Tracy L. Stepien. The code is 
platform independent and written in MATLAB, which requires a license.
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